Immune Activation in HIV-1 Infected Patients Under AntiRetroviral Treatment (ACTIVIH)
Immune Activation in HIV-1 Infected Patients Under AntiRetroviral Treatment: Etiologic Factors, Forms and Potential Association With Chronic Comorbidities Unrelated to Immune Deficiency.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34295
- University hospital Montpellier
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Age > or = 45 years
- HIV-1 infection
- Number of T CD4+ lymphocytes before antiretroviral treatment < 350 cells/mm3
- Current number of T CD4+ lymphocytes > 200 cells / mm3 for 6 moths before inclusion
- Efficient and well tolerated antiretroviral treatment for more than 24 months
- HIV-1 viral load < 50 copies/ml for more than 24 months before inclusion
- Patient able to understand the nature, the objective and the methods of the study
- Patient having signed the informed consent
- Affiliation to French Social Security System
Exclusion criteria:
- Patient having a current evidence of II to IV rank of the ANRS scale clinical condition
- Patient having a current evidence of III to IV rank of the ANRS scale biological condition
- Patient has a current evidence of an active coinfection
- Patient has a current (active) diagnosis of acute hepatitis due to any cause. Patients with chronic hepatitis, including chronic hepatitis B and/or C, may enter the study as long as they have stable liver function tests and undetectable viral load of hepatitis B and/or C
- Patient has a cirrhosis
- Patient presents with a non infectious pathology that might give immune modifications
- Patient using immuno-modulator therapy or chemotherapy
- Patient is currently participating or has participated in a study (within the exclusion period defined by this study)
- Patient is pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treated HIV-1 infected patients
Treated HIV-1 infected patients for Blood test
|
Blood test
|
|
Experimental: No treated HIV-1 infected patients
No treated HIV-1 infected patients for Blood test
|
Blood test
|
|
Experimental: Healthy witness
Healthy witness for Blood test
|
Blood test
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Infection of novo persistent
Time Frame: Infection of novo persistent the day of inclusion
|
Etiologic factors of persistent immune activation in treated HIV-1 infected patients (obstinacy of the infection of new cells T CD4 +, microbial translocation, active coinfection, immunosenescence, lymphopenia T CD4 +, deficit in lymphocytes Treg) on a day: the day of the inclusion
|
Infection of novo persistent the day of inclusion
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Microbial translocation
Time Frame: Microbial translocation the day of inclusion
|
Microbial translocation (DNA bacterial plasma derivative)
|
Microbial translocation the day of inclusion
|
|
Diagnosis immunizing activation
Time Frame: Diagnosis immunizing activation the day of inclusion
|
Activation T CD4 and T CD8, B, NK
|
Diagnosis immunizing activation the day of inclusion
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
No immunological response to treatment
Time Frame: No immunological response to treatment the day of inclusion
|
Measurement of circulating CD4 +
|
No immunological response to treatment the day of inclusion
|
|
Renal Review
Time Frame: Renal Review the day of inclusion
|
Estimated glomerular filtration rate, Na / K / Cl / alkaline reserve, blood uric acid, typing with proteinuria, albuminuria, creatinine, phosphorus reabsorption, urine dipstick
|
Renal Review the day of inclusion
|
|
Bone balance
Time Frame: Bone balance the day of inclusion
|
Determination of Calcium and phosphate levels in fasting, PTH, TSH, 25hydroxy vitamin D, testosterone (male), estradiol (female)
|
Bone balance the day of inclusion
|
|
Metabolic syndrome assessment
Time Frame: Metabolic syndrome assessment the day of inclusion
|
Metasting blood glucose, HbA1c, triglycerides, LDL cholesterol, HDL cholesterol
|
Metabolic syndrome assessment the day of inclusion
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: JACQUES REYNES, PU PH, Univerty Hospital Montpellier
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 9187
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.